HLX07 + carboplatin + pemetrexed

HLX07 + carboplatin + pemetrexed is a combination regimen under clinical investigation for the treatment of advanced solid tumors. HLX07 is a recombinant humanized monoclonal antibody targeting the epidermal growth factor receptor (EGFR), developed by Henlius. It was engineered from cetuximab to reduce immunogenicity and improve affinity, aiming to inhibit tumor cell proliferation by blocking EGFR signaling pathways[1][2][3][6]. Carboplatin and pemetrexed are established chemotherapeutic agents; carboplatin is a platinum-based DNA crosslinker, while pemetrexed inhibits folate-dependent enzymes involved in nucleotide synthesis. The combination aims to leverage the targeted action of HLX07 with the cytotoxic effects of chemotherapy for enhanced antitumor efficacy[5].